๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Fuzhou
Clinical trial register · China

Clinical Trials in Fuzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca62 First Affiliated Hospital of Fujian Medical University45 Merck Sharp & Dohme LLC39 Fujian Medical University Union Hospital39 Fujian Cancer Hospital35
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Fuzhou

1018 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study
NCT07010393Thyroid Neoplasms
DrugsLarotrectinib·Pralsetinib·Selpercatinib·Dabrafenib
Fujian Medical University
Phase 4
335
Fuzhou
2025-07-01
Recruiting
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
NCT06855277Prostate Cancer
DrugsAAA817·ARPI
Novartis Pharmaceuticals
Phase 3
940
Fuzhou, Guangzhou, Wuhan, Nanjing, Shenyang, Chengdu, Hangzhou, Beijing
2025-07-01
Not yet open
BR Combined With OR in Treatment-naรฏve Marginal Zone Lymphoma
NCT07008053Marginal Zone Lymphomas
Tianjin Medical University Cancer Institute and Hospital
Phase 2
37
Fuzhou, Shijiazhuang, Changsha, Jinan, Qingdao, Tianjin
2025-07
Recruiting
A Phase โ…ก Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
NCT06962865Non-Small Cell Lung Cancer
RemeGen Co., Ltd.
Phase 2
80
Beijing, Binzhou, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou
2025-06-30
Recruiting
A Study of DC50292A Tablet in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors
NCT07071090Solid Tumor Malignancies
Heronova Pharmaceuticals
Phase 1
32
Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Changsha, Jinan, Hangzhou
2025-06-30
Recruiting
PH-DyPred: A Multimodal Dynamic Risk Prediction Study in Pulmonary Hypertension
NCT07131241Pulmonary Hypertension
First Affiliated Hospital of Fujian Medical University
Observational
1,000
Fuzhou
2025-06-27
Recruiting
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
NCT07082738Chronic Obstructive Pulmonary Disease (COPD)
AstraZeneca
Phase 2
987
Baotou, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou
2025-06-27
Recruiting
The Application of "HUAXI Hole 1" in Reverse-sequence Endoscopic Nipple-sparing Mastectomy With Direct-to-implant Breast Reconstruction
NCT06995118Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Du Zhenggui
Not applicable
337
Fuzhou, Guangzhou, Anyang, Zhengzhou, Changsha, Hohhot, Suzhou, Nanchang
2025-06-17
Recruiting
Feasibility of Enhanced Recovery After Surgery Without Prophylactic Abdominal Drainage Tubes After Laparoscopic Distal Gastrectomy For Gastric Cancer
NCT07029269Gastric Adenocarcinoma, Laparoscopic Gastrectomy, Complications
Zuoyi Jiao
Phase 3
454
Beijing, Fuzhou, Lanzhou, Zhejiang, Xi'an
2025-06-16
Recruiting
ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
NCT07327034Hepatocellular Carcinoma (HCC)
DrugABSK-011
Abbisko Therapeutics Co, Ltd
Phase 2
141
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Guilin, Liuzhou, Nanning
2025-06-13
Recruiting
A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
NCT07010263Small Cell Lung Cancer
DrugBevacizumab
Akeso
Phase 3
560
Beijing, Beijin, Chongqing, Fuzhou, Longyan, Zhangzhou, Lanzhou, Jiangmen
2025-06-13
Recruiting
A Clinical Trial of SIBP-A19 Injection in the Treatment of Advanced Malignant Solid Tumor Patients
NCT06990464Advanced Solid Tumors
Shanghai Institute Of Biological Products
Phase 1
156
Fuzhou
2025-06-11
Recruiting
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]
NCT06783647Advanced Solid Tumour
Nanjing Leads Biolabs Co.,Ltd
Phase 2
250
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Guilin, Nanning, Harbin
2025-06-11
Recruiting
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
NCT06943872Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsSonrotoclax·Obinutuzumab·Venetoclax·Rituximab
BeOne Medicines
Phase 3
630
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Shijiazhuang, Harbin
2025-06-11
Recruiting
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
NCT06340568Endometrial Cancer
DrugsDoxorubicin·Paclitaxel
BioNTech SE
Phase 3
480
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Shantou
2025-06-10
Recruiting
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
NCT06993844Advanced Solid Tumors, Advanced Breast Cancer
DrugFulvestrant
Ensem Therapeutics
Phase 1/2
233
Beijing, Fuzhou, Guangzhou, Shandong, Shanghai
2025-06-10
Active, closed
A Phase I Study of SHR-4712 in Patients With Advanced Solid Tumors
NCT06993116Advanced Solid Tumor
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase 1
15
Fuzhou, Changsha
2025-06-09
Recruiting
A Multicenter Study of AHB-137 Injection Combined With Other Hepatitis B Drugs
NCT07069569Chronic Hepatitis B
DrugsHepatitis B vaccine·PEG-IFNฮฑ·AHB-137
Ausper Biopharma Co., Ltd.
Phase 2
200
Beijing, Chongqing, Fuzhou, Guangzhou, Shenzhen, Zunyi, Wuhan, Changchun
2025-06-08
Recruiting
Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
NCT06793917Gastric Cancer
DrugsLevo-Leucovorin·Oxaliplatin·Bevacizumab·Paclitaxel
Fujian Cancer Hospital
Phase 3
269
Fuzhou
2025-06-07
Recruiting
A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
NCT06891833HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2/3
985
Bengbu, Hefei, Chongqing, Fuzhou, Guangzhou, Shenzhen, Liuzhou, Nanning
2025-06-05
Recruiting
Cohort Observing Mechanisms, Progression and Sequelae of Valvular Heart Disease
NCT07267117Heart Valve Disease, Mitral Valve (MV) Regurgitation, Mitral Valve Disease, Mitral Valve Stenosis
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
10,000
Fuzhou, Wuhan, Changsha, Shenyang, Xi'an, Qingdao, Chengdu, รœrรผmqi
2025-06-01
Recruiting
Combined Use of Bacteroides Fragilis and BCAAs on HBsAg Clearance
NCT07257562Chronic Hepatitis B
DrugBranched-Chain Amino Acids
First Affiliated Hospital of Fujian Medical University
Observational
40
Fuzhou
2025-06-01
Not yet open
Extent of Lymph Node Dissection for Advanced Right-Sided Colon Cance
NCT06986538Advanced Right-sided Colon Cancer, the Extent of Lymph Node Dissection
Sixth Affiliated Hospital, Sun Yat-sen University
Not applicable
1,064
Beijing, Fuzhou, Guangzhou, Qingyuan, Shaoguan, Zhaoqing, Nanning, Guiyang
2025-06-01
Recruiting
Dual-Channel Near-Infrared Autofluorescence Imaging and AI Analysis to Locate Parathyroid Glands (PTFinder)
NCT07010380Thyroid Neoplasms, Hyperparathyroidism, Parathyroid Gland
Bo Wang,MD
Observational
180
Fuzhou
2025-06-01
Active, closed
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
NCT06970743Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsChlorambucil·Tacabrutideg·Methylprednisolone·Bendamustine
BeOne Medicines
Phase 3
153
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Meizhou, Shenzhen, Nanning
2025-05-29
Recruiting
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
NCT06780098Lung Neoplasm
DrugsR-DXd·Ifinatamab Deruxtecan·Paclitaxel
Merck Sharp & Dohme LLC
Phase 2
144
Beijing, Chongqing, Fuzhou, Nanning, Zhengzhou, Nanjing, Shanghai
2025-05-28
Recruiting
Tubeless Anesthesia in Preventing Lung Complications in Patients Undergoing Surgery for Early-Stage Lung Cancer
NCT07024433Lung Cancer Patients
Fujian Medical University Union Hospital
Not applicable
224
Fuzhou
2025-05-25
Recruiting
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
NCT06952504Endometrial Cancer
DrugsSacituzumab tirumotecan·Cisplatin·Carboplatin·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
1,123
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shantou, Zhanjiang
2025-05-22
Recruiting
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
NCT06901531Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsZolbetuximab·Oxaliplatin·Capecitabine·Pembrolizumab
Astellas Pharma Global Development, Inc.
Phase 3
500
Hefei, Fuzhou, Guangzhou, Harbin, Zhenngzhou, Wuhan, Xining, Shanghai
2025-05-22
By invitation
Effects of Omega-3 Fatty Acids on Acute Graft-versus-Host Disease After Allogeneic Stem Cell Transplantation.
NCT07162688Graft-Versus-Host Disease(GVHD)
Fujian Medical University
Phase 1/2
30
Fuzhou
2025-05-16
Active, closed
Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)
NCT06898957Small Cell Lung Cancer
DrugsTam-Peli·Tarlatamab·Durvalumab
Amgen
Phase 1
29
Jinan, Chengdu, Fuzhou
2025-05-16
Recruiting
Research on the Application of 68Ga-PSMA-CYC PET Imaging in the Diagnosis, Staging, and Restaging of Prostate Cancer
NCT07056790Prostate CA
First Affiliated Hospital of Fujian Medical University
Phase 1/2
40
Fuzhou
2025-05-15
Recruiting
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
NCT06925737Prostate Cancer, Prostatic Neoplasms
DrugsIfinatamab Deruxtecan·Prednisone·Paclitaxel
Merck Sharp & Dohme LLC
Phase 3
1,440
Beijing, Chongqing, Fuzhou, Guangzhou, Zhuhai, Nanning, Zhengzhou, Wuhan
2025-05-13
Recruiting
Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
NCT06801236Prostate Cancer (Adenocarcinoma), mCRPC (Metastatic Castration-resistant Prostate Cancer)
Acerand Therapeutics (Hong Kong) Limited
Phase 1
88
Fuzhou
2025-05-12
Recruiting
ICP-332 in Subjects With Non-segmental Vitiligo
NCT07047612Non Segmental Vitiligo
DrugICP-332
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2/3
603
Wuhu, Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Luoyang, Nanyang
2025-05-09
Recruiting
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06935357Immunoglobulin A Nephropathy (IgAN)
DrugFelzartamab
Biogen
Phase 3
454
Fuyang, Hefei, Beijing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Shenzhen
2025-05-08
Recruiting
Crisugabalin for Radiotherapy-Related Neuropathic Pain
NCT06766916Neuropathic Pain
DrugsCrisugabalin·Pregabalin
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
172
Fuzhou, Guangzhou, Zhongshan, Nanning, Zhengzhou, Changsha
2025-05-07
Recruiting
PSMA PET/MRI-Guided Prostate Biopsy for PI-RADS โ‰ค3 and Prior Negative Biopsy
NCT06923657Prostate Cancer Screening, PSMA-PET
First Affiliated Hospital of Fujian Medical University
Not applicable
230
Fuzhou
2025-05-07
Recruiting
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
NCT06921785Hepatocellular Carcinoma
DrugsTremelimumab·Rilvegostomig·Atezolizumab·Bevacizumab
AstraZeneca
Phase 3
1,220
Beijing, Changchun, Changsha, Chengdu, Chifeng, Chongqing, Deyang, Fuzhou
2025-05-06
Recruiting
QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
NCT06749899Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer
DrugsIparomlimab and Tuvonralimab·Gemcitabine·Cisplatin
Sun Yat-Sen University Cancer Center
Phase 3
580
Fuzhou, Dongguan, Foshan, Guangzhou, Zhongshan, Nanning, Guiyang, Wuhan
2025-05-04
Recruiting
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
NCT06892548Advanced Lung Cancer
DrugsBNT324·Pumitamig
BioNTech SE
Phase 1/2
594
Hefei, Beijing, Fuzhou, Nanning, Weihui, Zhengzhou, Jingzhou, Xiangyang
2025-05-02
Recruiting
CHina Adrenal Venous saMPling InvestigatiON
NCT07252284Hyperaldosteronism, Adrenal Venous Sampling, Adrenalectomy
Chinese Academy of Medical Sciences, Fuwai Hospital
Observational
5,000
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Foshan, Guangzhou
2025-05-01
Recruiting
Clinical Outcomes of Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Extended Lymphadenectomy Beyond D2 for Locally Advanced Gastric Cancer (FUGES-30)
NCT06945718Gastric Cancer, Surgery
Fujian Medical University
Observational
760
Fuzhou
2025-05-01
By invitation
Clinical Efficacy of Pucotenlimab Combined With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07356466Gastric (Stomach) Cancer
DrugsPucotenlimab·Tegafur Gimeracil Oteracil·Lenvatinib·Oxaliplatin
Fujian Medical University
Phase EARLY_PHASE1
100
Fuzhou
2025-05-01
Recruiting
Quantitative Intra-operative Assessment of Parathyroid Perfusion Using Indocyanine Green (ICG) Fluorescence Imaging
NCT07010341Thyroid Surgery
Fujian Medical University
Observational
210
Fuzhou
2025-05-01
Active, closed
PD-1 Inhibitors +Venetoclax+CAG Regimens in R/R T-ALL
NCT07541755Acute T Lymphoblastic Leukemia (T-ALL)
Fujian Medical University Union Hospital
Phase 3
40
Fuzhou
2025-05-01
Not yet open
A Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Inhaled H057 in the Treatment of Acute Exacerbations of Bronchiectasis
NCT06958861Acute Exacerbations of Bronchiectasis
Shanghai Huilun Pharmaceutical Co., Ltd.
Phase 2
180
Fuyang, Hefei, Fuzhou, Guangzhou, Shenzhen, Baise City, Shijiazhuang, Nanyang
2025-05
Recruiting
Robot-Assisted Tai Chi for Upper Limb Rehabilitation in Stroke Patients
NCT06897631Stroke
Jing Tao
Not applicable
120
Fuzhou
2025-04-29
Recruiting
Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
NCT06829771Diffuse Large B Cell Lymphoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
90
Bengbu, Maโ€™anshan, Beijing, Fuzhou, Quanzhou, Lanzhou, Guangzhou, Liuzhou
2025-04-23
Active, closed
Prospective Clinical Trial of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer
NCT07117760Prostate Cancer
Drugs225Ac-LNC1011·68Ga-PSMA-11
First Affiliated Hospital of Fujian Medical University
Phase 1/2
16
Fuzhou
2025-04-22
Recruiting
IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
NCT06974812Unresectable Locally Advanced or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1/2
250
Fuzhou, Changsha, Shanghai
2025-04-18
Recruiting
A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma
NCT06860971Thyroid Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
144
Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Gui'lin, Liuzhou
2025-04-18
Recruiting
Efficacy and Safety of Transcranial Magnetic Stimulation in Treatment of Alzheimer's Disease
NCT07324161Alzheimer s Disease
Fujian Medical University Union Hospital
Not applicable
81
Fuzhou
2025-04-16
Active, closed
Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere
NCT06900543Unresectable Hepatocellular Carcinoma
DrugNRT6003
Chengdu New Radiomedicine Technology Co. LTD.
Phase 3
108
Fuzhou, Guangzhou, Zhengzhou, Wuhan, Nanjing, Shenyang, Xiโ€™an, Chengdu
2025-04-15
Active, closed
A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese Males
NCT06866574Penile/Perineal /Perianal Intraepithelial Neoplasia, Anal Intraepithelial Neoplasia, Penile/Perianal/Perineal Cancer, Anal Cancer
Xiamen University
Phase 3
9,300
Fuzhou, Chengdu, Kunming, Hangzhou
2025-04-11
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
NCT06868277Carcinoma, Non-Small Cell Lung
DrugsRilvegostomig·Pembrolizumab
AstraZeneca
Phase 3
830
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou
2025-04-10
Recruiting
Motor-Cognitive Interactive Upper Limb Robot Rehabilitation for Post-Stroke Motor Dysfunction
NCT06876597Stroke
Lidian Chen
Not applicable
1,047
Fuzhou
2025-04-08
Recruiting
Clinical Studies for the Treatment of Advanced Solid Tumors
NCT06825494Advanced Solid Tumor
DrugsLM-108·Penpulimab·Oxaliplatin·Capecitabine
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1/2
194
Hefei, Beijing, Fuzhou, Lanzhou, Wuwei, Shenzhen, Nanning, Tangshan
2025-04-08
Recruiting
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
NCT06801834Extensive Stage Small Cell Lung Cancer (ES-SCLC)
DrugsAmrubicin·Lurbinectedin·Topotecan·Sacituzumab Govitecan
Gilead Sciences
Phase 3
695
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin
2025-04-04
Recruiting
A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy
NCT06839066Nasopharyngeal Carcinoma (NPC)
DrugsHLX43 3·HLX43 2·HLX43 1
Shanghai Henlius Biotech
Phase 2
70
Fuzhou, Dongguan, Guangzhou, Shenzhen, Nanning, Guiyang, Wuhan, Changsha
2025-04-02
Recruiting
Sequential Study of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer
NCT07363486Prostate Cancer
Drug225Ac-LNC1011
First Affiliated Hospital of Fujian Medical University
Phase 1/2
9
Fuzhou
2025-04-01
By invitation
Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP
NCT06859099Polyneuropathy, Inflammatory Demyelinating, Chronic
DrugRiliprubart
Sanofi
Phase 3
300
Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Wuhan
2025-04-01
Active, closed
Clinical Study of 177Lu-JH040182 in Patients With FAP-Positive Malignancies
NCT07681141Patients With Advanced Metastatic FAP-Positive Tumors
First Affiliated Hospital of Fujian Medical University
Phase 1
3
Fuzhou
2025-04-01
Active, closed
Serological Autoantibodies in Early Kidney Cancer Diagnosis and Prognosis: A Multicenter Study
NCT06917560Renal Carcinoma, Serology, Autoantibody
First Affiliated Hospital of Fujian Medical University
Observational
400
Fuzhou
2025-04-01
Recruiting
Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
NCT07152041Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), Childhood Leukemia, Acute Lymphoblastic
DrugOlverembatinib
Institute of Hematology & Blood Diseases Hospital, China
Phase 3
150
Hefei, Chongqing, Fuzhou, Guangzhou, Guiyang, Wuhan, Changsha, Nanjin
2025-03-28
Recruiting
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment
NCT06750289Eosinophilic Asthma
AstraZeneca
Phase 3
400
Beijing, Changsha, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Huizhou
2025-03-28
Recruiting
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
NCT06989112Endometrial Cancer
DrugsRilvegostomig·Trastuzumab deruxtecan·Carboplatin·Pembrolizumab
AstraZeneca
Phase 3
600
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou
2025-03-27
Recruiting
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
NCT06644781Esophageal Squamous Cell Carcinoma
DrugsIrinotecan Hydrochloride·Ifinatamab Deruxtecan·Paclitaxel
Daiichi Sankyo
Phase 3
510
Anyang, Beijing, Changchun, Changzhou, Chengdu, Fuzhou, Harbin, Hefei
2025-03-27
Recruiting
Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis
NCT06842199Plaque Psoriasis Patients
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 3
383
Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Guangzhou, Liuzhou, Guiyang
2025-03-20
Recruiting
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
NCT06819007Ovarian Cancer
DrugsTrastuzumab deruxtecan·Bevacizumab
Daiichi Sankyo
Phase 3
582
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou
2025-03-19
Recruiting
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
NCT06883305Chronic Obstructive Pulmonary Disease (COPD)
DrugTezepelumab
AstraZeneca
Phase 3
990
Anyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou
2025-03-18
Recruiting
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819878Moderately to Severely Active Crohns Disease
DrugAfimkibart
Hoffmann-La Roche
Phase 3
600
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2025-03-17
Recruiting
A Clinical Trial of TQB2102 for Injection in Gynecological Tumors With Recurrent/Metastatic Advanced
NCT06798207Gynecological Tumors
DrugTQB2102
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 2
170
Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Meizhou, Qingyuan, Nanning
2025-03-13
Active, closed
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
NCT06764485Metastatic Castration-resistant Prostate Cancer
DrugsAbiraterone·Enzalutamide·Paclitaxel
Celgene
Phase 3
960
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Huizhou, Changzhou, Nanjing
2025-03-13
Recruiting
Newly-diagnosed Pediatric T-cell ALL Protocol
NCT06855810Acute Lymphoblastic Leukemia, Childhood Leukemia, Acute Lymphoblastic, T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2/3
610
Hefei, Chongqing, Fuzhou, Guangzhou, Nanning, Guiyang, Wuhan, Changsha
2025-03-11
Recruiting
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
NCT06772623Non Small Cell Lung Carcinoma
DrugsBudigalimab·Telisotuzumab Adizutecan·Pemetrexed·Cisplatin
AbbVie
Phase 1/2
252
Beijing, Fuzhou, Liuzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Nanchang
2025-03-06
Recruiting
A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tumors
NCT06716138Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration
Avistone Biotechnology Co., Ltd.
Phase 1
96
Fuzhou, Guangzhou, Shanghai, Chengdu
2025-03-06
Recruiting
Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
NCT06882057Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic, B Cell Acute Lymphoblastic Leukemia (B-ALL)
Institute of Hematology & Blood Diseases Hospital, China
Phase 2/3
3,000
Hefei, Chongqing, Fuzhou, Guangzhou, Nanning, Guiyang, Wuhan, Changsha
2025-03-03
Recruiting
A Phase โ…ข Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
NCT06764875HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
DrugsRilvegostomig·Trastuzumab deruxtecan·Trastuzumab·Oxaliplatin
AstraZeneca
Phase 3
840
Anyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou
2025-03-01
Recruiting
Metabolic and Immunomic Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma
NCT07188077Primary Central Nervous System Lymphoma (PCNSL), Diffuse Large B-Cell Lymphoma
Ting YANG
Observational
20
Fuzhou
2025-03-01
Recruiting
Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer
NCT06521866Advanced Colorectal Carcinoma, Immunotherapy
Fudan University
Phase 2
208
Fuzhou, Xiamen, Lanzhou, Zhengzhou, Huaian, Jinan, Taian, Shanghai
2025-03-01
Not yet open
PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM
NCT06788171Colorectal Cancer Liver Metastasis
DrugsOxaliplatin·Capecitabine·Bevacizumab·Tislelizumab
Fujian Cancer Hospital
Phase 2
35
Fuzhou
2025-03-01
Recruiting
Dosimetry and Preliminary Clinical Application Study of a Novel Probe Targeting CD73
NCT06995976Malignant Tumour
Drug18F-FDG
First Affiliated Hospital of Fujian Medical University
Phase EARLY_PHASE1
30
Fuzhou
2025-03-01
Recruiting
Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) as a Local Salvage Therapy for Large Lesions in Relapsed and Refractory Diffuse Large B-Cell Lymphoma
NCT07198230Diffuse Large B-Cell Lymphoma, Relapsed and Refractory, Transarterial Chemoembolization
Ting YANG
Observational
10
Fuzhou
2025-03-01
Active, closed
Defining Benchmarks for Gastric Cancer Patients Underwent Minimal Invasive Gastrectomy
NCT06938139Gastric Adenocarcinoma, Surgery, Laparoscopic
Fujian Medical University
Observational
90,000
Fuzhou
2025-03-01
Not yet open
A Clinical Study Comparing Semaglutide Injection and Wegovyยฎ for Weight Management in Obese Subjects
NCT06738979Obesity
DrugsWegovy·Semaglutide
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
408
Hefei, Xuancheng, Chongqing, Fuzhou, Lanzhou, Guilin, Liuzhou, Nanning
2025-03
Recruiting
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
NCT06780137Small Cell Lung Cancer
DrugsGocatamig·Ifinatamab Deruxtecan·Durvalumab
Merck Sharp & Dohme LLC
Phase 1/2
327
Beijing, Fuzhou, Nanjing, Shanghai, Chengdu, Hangzhou
2025-02-27
Recruiting
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
NCT06767514Non-Small Cell Lung Cancer
DrugsPembrolizumab·Bevacizumab
Summit Therapeutics
Phase 3
780
Fuyang, Beijing, Fuzhou, Guangzhou, Nanning, Guiyang, Haikou, Harbin
2025-02-27
Recruiting
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
NCT06780670Prostate Cancer
DrugAAA817
Novartis Pharmaceuticals
Phase 2/3
443
Fuzhou, Wuhan, Nanjing, Shenyang, Xian, Chengdu, Beijing, Guangzhou
2025-02-27
Recruiting
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
NCT06731478Gastric Cancer, Gastroesophageal Junction Cancer
DrugsTrastuzumab deruxtecan·Trastuzumab·Pembrolizumab
Daiichi Sankyo
Phase 3
726
Beijing, Changzhou, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou
2025-02-27
Recruiting
Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
NCT06846996HER2-positive Gastric Cancer, HER2-positive Gastroesophageal Junction
DrugTrastuzumab deruxtecan
Daiichi Sankyo
Observational
260
Beijing, Changchun, Changzhi, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei
2025-02-27
Active, closed
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC
NCT06745323Small Cell Lung Cancer (SCLC)
DrugTarlatamab
Amgen
Phase 2
252
Beijing, Fuzhou, Guangzhou, Harbin, Changsha, Taiyuan, Chengdu, Tianjin
2025-02-26
Recruiting
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
NCT06646276Extensive-Stage Small Cell Lung Cancer
DrugsAtezolizumab·Etoposide·Nivolumab·Carboplatin
Bristol-Myers Squibb
Phase 3
530
Beijing, Chongqing, Fuzhou, Xiamen, Shantou, Harbin, Wuhan, Changsha
2025-02-25
Recruiting
A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy
NCT06797297Melanoma
DrugsIBI363·Pembrolizumab
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2
180
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Shijiazhuang, Harbin
2025-02-24
Recruiting
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
NCT06741644Advanced Solid Tumors
DrugsLeucovorin·Irinotecan·Etoposide·Nab-paclitaxel
CStone Pharmaceuticals
Phase 1/2
800
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2025-02-24
Recruiting
Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)
NCT06809764Non-small Cell Lung Cancer
Daiichi Sankyo
Observational
150
Beijing, Changsha, Fuzhou, Guangdong, Guangzhou, Hangzhou, Hebei, Hefei
2025-02-21
Recruiting
A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
NCT06839105Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid Tumor
DrugsAWT020·Taxol·Oxaliplatin·Capecitabine
Shanghai Junshi Bioscience Co., Ltd.
Phase 1
214
Fuzhou, Guangzhou, Harbin, Luoyang, Wuhan, Changsha, Nanchang, Changchun
2025-02-21
Active, closed
Toripalimab vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
NCT06712888Nasopharyngeal Carcinoma (NPC)
Sun Yat-sen University
Phase 3
466
Fuzhou, Guangzhou, Shenzhen, Zhanjiang, Nanning, Guiyang, Changsha, Chengdu
2025-02-17
Recruiting
Effect of Low-dose EsketaMine on dElirium in High-risk Elderly Patients uNdergoing elecTive Surgery (ELEMENT)
NCT06817239Delirium in Old Age, Delirium, Postoperative, Anesthesia, Cognitive Dysfunction
DrugEsketamine
Nanfang Hospital, Southern Medical University
Not applicable
1,670
Fuzhou, Guangzhou, Ganzhou
2025-02-12
Recruiting
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
NCT06712355Extensive-stage Small-cell Lung Cancer
DrugsPumitamig·Atezolizumab·Etoposide·Carboplatin
BioNTech SE
Phase 3
621
Changchun, Baoding, Beijing, Bengbu, Fuzhou, Guangzhou, Hangzhou, Haโ€™erbin
2025-02-03
Rows per page Showing 301–400 of 1018
Previous 2 3 4 5 6 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/fuzhou?page=4

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,018 of those studies with a site in Fuzhou.

How many clinical trials are recruiting in Fuzhou?

594 of the 1,018 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 114 have not yet opened recruitment, 287 are active but closed to new participants, and 23 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.